The immune microenvironments of AML with complete remission (AML-CR) and AML with no response (AML-NR) are highly disparate, and the E3 ubiquitin ligase RNF149 alters the immune milieu of AML, triggering dysfunction in CD8+ T cells [45]. Here, CD8A is linked to acute myeloid leukemia.